Key Takeaways DuPont will supply MemCor MBR systems for upgrades at Eccles, Salford and Wigan in North West England.Wigan, serving over 437,000 people, will become the UK's largest MBR plant after expansion.DD's MBR tech boosts effluent quality, efficiency and scale benefits with 300 global installations.DuPont de Nemours, Inc.’s (DD) Water Solutions has been chosen by United Utilities to supply its MemCor membrane bioreactor (MBR) systems for major wastewater treatment expansion at three facilities in Nort ...

【DT新材料】 获悉，2月10日， 杜邦 正式发布2025年全年及第四季度业绩公告。数据显示， 公司全年净亏损达7.38亿美元，折合人民币约51亿元 ，去年同期为7.38亿美元净收入。 2025年全年业绩方面： 净销售额：68.49亿美元（约合473亿元），同比增长2%，其中医疗保健与水技术板块是主要增 长动力； 核心盈利：GAAP持续经营收入9800万美元，同比暴涨202%，主要得益于核心业务板块盈利提 升及有效税率下降； 经营性EBITDA：16.28亿美元，同比增长6%，有机增长和生产力提升的成效显著，仅部分被增 长投资抵消； 重点的7.38亿美元（约51亿元）净亏损，全部来自主动剥离的终止经营业务，这部分亏损达8.36 亿美元，主要包括电子业务分拆，以及芳纶业务出售。 其中，芳纶出售事件，是2025年8月，杜邦正式宣布达成最终协议， 将芳纶业务出售给TJC旗下 投资组合公司Arclin，交易预计于2026年一季度末完成。 这笔交易的对价十分明确：包括约12亿美元的税前现金（将按惯例调整）、TJC提供的3亿美元 票据，以及未来Arclin控股公司价值3.25亿美元的少数股权，交易总估值约18亿美元。 通 ...

Group 1 - The small business owner in Connecticut supplies equipment and supplies to restaurants and food service establishments, aiming to reallocate profits into a portfolio for passive retirement income [1] - The owner has a background in finance, having earned a CFA charter and CIPM certificate, and has experience in assisting firms with compliance to Global Investment Performance Standards (GIPS) [1] - The owner is sector agnostic and writes about any company they can understand, often based on personal investment considerations [1] Group 2 - The analyst has a beneficial long position in SBUX shares and is in the process of unwinding this position, expecting to be fully out within 30 days [2]

Healthcare and Medical Devices - The Healthcare & Water Technologies segment focuses on high-performance products for medical devices and water purification, addressing critical challenges like aging populations and water scarcity [32]. - DuPont completed the acquisition of Spectrum Plastics Group on August 1, 2023, enhancing its capabilities in specialty medical devices and components [34]. - The company also acquired Donatelle Plastics, LLC on July 28, 2024, further strengthening its position in the medical device market [34]. - In 2025, net sales for Healthcare Technologies and Water Technologies are expected to grow significantly, driven by increasing demand for efficient water purification solutions [38]. Diversified Industrials - The Diversified Industrials segment provides engineered products that enhance safety and operational efficiency across various markets, including aerospace and automotive [42]. - The company emphasizes market-driven innovation and advanced manufacturing capabilities to support new product development in Diversified Industrials [43]. - The Building Technologies business offers solutions for energy efficiency and durability in construction, contributing to the overall growth of the segment [46]. Employee and Talent Management - DuPont employs approximately 15,000 people globally, with a significant portion dedicated to the Aramids Business, reflecting the company's commitment to talent retention and development [62]. - DuPont's focus on health, safety, and employee well-being includes comprehensive wellness programs and a commitment to zero workplace injuries [67]. Financial Risk Management - The Company has significant exposure to foreign currency exchange rates, primarily with the euro (EUR), Chinese renminbi (CNY), Japanese yen (JPY), Canadian dollar (CAD), and Indian rupee (INR) [377]. - As of December 31, 2025, the fair value of foreign currency contracts was $(10) million, with a sensitivity of $(163) million for a 10% adverse change in exchange rates [378]. - The net investment hedge for European operations would decrease in fair value by approximately $100 million if the U.S. dollar weakened by 10% as of December 31, 2025 [379]. - Interest rate swaps would decrease in fair value by approximately $35 million if floating rates appreciated by 10% as of December 31, 2025 [380]. - The Company has not sustained credit losses from instruments held at financial institutions, maintaining a policy to limit credit exposure with any one institution [382]. - No individual customer represented more than 5% of the Company's total outstanding receivables balance as of December 31, 2025, indicating a diverse customer base [384]. - The Company continuously evaluates the credit standing of financial institutions and monitors exposures against established limits [383]. - The Company uses derivative instruments to manage financial market risks and minimize volatility in financial results [376]. - The Company has established procedures for hedging foreign currency, interest rate, and commodity price risks on a case-by-case basis [376]. - The Company maintains strong credit controls and may require financial guarantees from customers in certain circumstances [385].

Core Insights - DuPont's FilmTec™ Fortilife™ XC160UHP reverse osmosis elements have been named a finalist in the 2026 Edison Awards for their innovative approach to industrial wastewater treatment and reuse [1] - The XC160UHP elements are designed to operate under ultra-high-pressure conditions, providing high water recovery and supporting industrial users in meeting stringent discharge regulations while reducing energy consumption and operational costs [1] - The Edison Awards recognize excellence in innovation, with this year's finalists evaluated on concept, value, and impact by an independent panel of experts [1] Company Overview - DuPont is a global innovation leader, providing advanced solutions across key markets including healthcare, water, construction, and transportation [1] - The company’s technologies help purify over 50 million gallons of water every minute in 112 countries, addressing challenges faced by water treatment municipalities and industrial water users [1] - DuPont is focused on innovating solutions that balance growing water and energy demands, with products supporting electricity production, lithium, and green hydrogen [1]

Core Viewpoint - DuPont's stock price reached a historic high of $51.63 on February 11, 2026, driven by strong quarterly earnings and optimistic guidance for 2026 [1] Stock Price Movement Reasons - The fourth quarter performance exceeded expectations, with adjusted earnings per share of $0.46, surpassing analyst estimates of $0.43, and net sales of $1.69 billion meeting expectations, primarily due to growth in the healthcare sector and business restructuring [2] - The company provided a positive earnings outlook for 2026, projecting adjusted earnings per share between $2.25 and $2.30, above the analyst forecast of $2.14, and net sales guidance of $7.08 billion to $7.14 billion, exceeding the market expectation of $7.06 billion [2] - Morgan Stanley raised DuPont's target price from $44 to $52, further enhancing market optimism [2] - A market style shift occurred, with the Dow Jones Industrial Average performing strongly while the Nasdaq index weakened, benefiting DuPont as a leader in traditional industrial materials amid a rotation of funds towards value sectors [2] Financial Status - Despite a negative net profit of $114 million for the fourth quarter of 2025, the market focused on the company's adjusted profitability and future growth potential, with a gross margin maintained at 31.13%, indicating strong cost control [3] Future Development - The record high stock price of DuPont is attributed to a combination of exceeding performance expectations, optimistic guidance, favorable broker ratings, and market style shifts [4] - Investors should monitor the achievement of the 2026 performance targets and the progress of business restructuring, such as the spin-off of the electronics business [4]

Core Viewpoint - DuPont de Nemours, Inc. reported Q4 earnings that were well-received by investors, but the company's current prospects are not particularly strong, leading to a cautious outlook on its future performance [1]. Financial Performance - The Q4 earnings report from DuPont pleased investors, indicating a positive short-term reaction to the financial results [1]. Future Outlook - Despite the positive earnings report, the long-term prospects for DuPont are viewed as unimpressive, suggesting potential challenges ahead for the company [1].

Core Viewpoint - DuPont de Nemours, Inc. reported Q4 earnings that were well-received by investors, but the company's current prospects are not particularly strong, leading to a cautious outlook on its future performance [1]. Financial Performance - The Q4 earnings report indicated positive results that pleased investors, suggesting a short-term positive sentiment towards the company's financial health [1]. Future Outlook - Despite the positive Q4 earnings, the long-term prospects for DuPont are viewed as unimpressive, indicating potential challenges ahead for the company [1].

Core Viewpoint - DuPont de Nemours Inc. reported fourth-quarter earnings that slightly exceeded analyst expectations, resulting in a more than 2% increase in shares during premarket trading Group 1: Financial Performance - The company posted earnings per share of $0.46 for the quarter, surpassing the consensus estimate of $0.43 [1] - Revenue totaled $1.7 billion, aligning with analyst expectations of $1.69 billion [1] - Organic sales declined 1% year over year, impacted by a $30 million, or 2%, headwind related to a third-quarter timing shift [2] - Operating EBITDA increased 4% from the prior year to $409 million [2] Group 2: Future Guidance - For the first quarter of 2026, the company expects earnings per share of approximately $0.48, revenue of about $1.67 billion, and operating EBITDA of roughly $395 million [2] - For the full year 2026, the forecast for earnings per share is in the range of $2.25 to $2.30, with revenue expected between $7.08 billion and $7.14 billion [3] - Operating EBITDA for the year is anticipated to total between $1.72 billion and $1.75 billion [3]

Core Insights - DuPont de Nemours, Inc. reported a fourth-quarter 2025 loss from continuing operations of $108 million or 27 cents per share, an improvement from a loss of $291 million or 70 cents per share in the same quarter last year [1] - Adjusted earnings were 46 cents per share, exceeding the Zacks Consensus Estimate of 43 cents [1] Financial Performance - DuPont's net sales for the quarter reached $1,693 million, remaining flat year over year and surpassing the Zacks Consensus Estimate of $1,684.1 million [2] - Organic sales decreased by 1%, with a 1% positive impact from foreign currency offsetting a 1% decline in volume [2] - The company had cash and cash equivalents of $715 million at the end of the quarter, down approximately 60% year over year, while long-term debt was $3,134 million, down about 41% [5] Segment Performance - The Healthcare & Water Technologies segment reported net sales of $821 million, up 4% year over year, with organic sales growth of 3% and a 1% benefit from currency [3] - The Diversified Industrials segment recorded net sales of $872 million, down 3% year over year, with organic sales dipping 4% but partially offset by a 1% currency benefit [4] Future Outlook - For the first quarter of 2026, DuPont expects net sales of $1,670 million, operating EBITDA of $395 million, and adjusted EPS of 48 cents [6] - For the full year 2026, net sales are projected to be between $7,075 million and $7,135 million, with operating EBITDA estimated at $1,725 million to $1,755 million and adjusted EPS expected to be between $2.25 and $2.30 [6] Stock Performance - DuPont's shares have declined by 42.2% over the past year, compared to a 13.5% decline in the industry [7]